Cadrenal Therapeutics, Inc. (CVKD:NASDAQ) closed at $1.09 on October 16, 2026, up 12.37% on the day. The stock trades 92.3% below its 52-week high of $14.21 and 33.6% above its 52-week low of $0.816. Over the past year, it lost 92.0%. Cadrenal Therapeutics, Inc. is part of the Health Care sector.
| 5D | 1M | 3M | 6M | 1Y |
|---|---|---|---|---|
| +24.94% | -2.68% | -47.85% | -79.24% | -92.00% |
In 252 trading sessions since October 16, 2025, CVKD closed higher on 96 days (38%). Its best day was December 4, 2025 (+25.28%) and its worst was December 16, 2025 (-32.87%). The stock moved 10% or more in a single session 29 times. It opened at least 5% above the previous day's high 3 times.
Cadrenal Therapeutics Inc is focused on developing a novel therapy with orphan drug indication, tecarfarin, for the prevention of systemic thromboembolism (blood clots) of cardiac origin in patients with end-stage renal disease (on dialysis) and atrial fibrillation (irregular heartbeat) or AFib. Tecarfarin is an anticoagulant designed using a drug design process that targets a different pathway than most commonly prescribed drugs for the treatment of thrombosis and AFib.
Find more stocks like CVKD with the Spikes, Gaps, Breakouts and Performance Tracker scanners.
Based on end-of-day data. For information only, not investment advice.